

Product Information

Anti-Factor VII antibody, Mouse monoclonal clone HVII-1, purified from hybridoma cell culture

Catalog Number **F8146**

Product Description

Anti-Factor VII antibody, Mouse monoclonal (mouse IgG1 isotype) is derived from the HVII-1 hybridoma produced by the fusion of mouse Sp2/0-Ag14 myeloma cells and splenocytes from immunized BAB/c mice. Factor VII purified from human plasma was used as the immunogen.¹ [In this paper the antibody is referred to as MC-1476 (E.A.8.1)]. The isotype is determined by a double diffusion immunoassay using Mouse Monoclonal Antibody Isotyping Reagents, Catalog Number ISO2.

Anti-Factor VII antibody, Mouse monoclonal is a calcium-independent antibody and recognizes an epitope on the light chain of human factor VII. The antibody localizes factor VII, at molecular weight of 50 kDa, in an immunoblotting assay, under denaturing and non-reducing conditions.

Human coagulation factor VII is a single-chain glycoprotein (m.w. \approx 50,000) which is synthesized in the liver and secreted into the blood as a zymogen.² Similar to other vitamin K-dependent blood clotting factors, it contains 10 gamma-carboxyglutamic acid residues (Gla) located at the N-terminal region of the molecule. Cleavage of an Arg-Ile bond converts the zymogen into activated factor VII. The activated factor VII (factor VIIa) consists of a light chain, containing the Gla-domain and an epidermal growth factor domain, which is linked by a disulfide bond to a heavy chain, containing the serine protease catalytic domain.² The activation of factor VII is catalysed by factor XIIa, factor IXa, factor Xa and thrombin. In the presence of tissue factor and calcium ions, factor VIIa converts factor X to factor Xa and factor IX to factor IXa. These reactions constitute the initiation of the extrinsic blood coagulation pathway. Recombinant factor VIIa is now produced for the treatment of hemophilia A patients with inhibitors to factor VIII. The normal plasma concentration of factor VII is about 0.5 μ g/ml. Its half life is the shortest among the coagulation factors, i.e. \approx 5 hours, and the half life of factor VIIa is even shorter \approx 2.5 hours.

The level of factor VII can be determined by a conventional clotting assay, amidolytic assay, radioimmunoassay or ELISA. Recent epidemiological studies have shown a significant association between factor VII level and the development of ischemic heart disease. Consequently, factor VII level is considered as an independent risk factor.

Monoclonal antibodies against factor VII can be used for:

1. the preparation of factor VII - depleted plasma and for purification,
2. sandwich-type immunoassays when paired with Monoclonal Anti Factor VII, clone HVII-2, (Product No. F8271),
3. evaluation of patients with hereditary factor VII deficiency by an ELISA or RIA,
4. assay of factor VII level in patients with liver disease (a sensitive parameter of liver dysfunction),
5. epidemiological studies of the importance of factor VII level as a risk factor for coronary heart disease, cerebrovascular disease and peripheral vascular diseases,
6. determination of the activity state of factor VII *in-vivo* samples when used with a clotting assay.

Reagents

The product is provided as purified antibody in 10 mM HEPES, 140 mM NaCl, pH 7.4, containing 0.05% sodium azide as a preservative.

Precautions

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Product Profile

Protein Concentration: 4 mg/ml

The antibody, at a concentration of 1-5 µg/ml, specifically recognizes SDS-denatured, non-reduced human factor VII in blot transfers from gels loaded with human plasma following barium citrate adsorption and subsequent elution.

Storage

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. Storage in "frost-free" freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.*

References

1. Broze, G.J.Jr., et al., *J. Clin. Invest.*, **76**, 937 (1985). Note: In this paper the antibody is referred to as MB-1476 (E.A. 8.1).
2. Broze, G.J. Jr., and Majerus, P.W., *J. Biol. Chem.*, **255**, 1242 (1980).

DS,PHC 08/15-1